No Data
No Data
No Data
Lake Street Sticks to Their Buy Rating for Harrow Health (HROW)
Harrow Announces Centers for Medicare & Medicaid Service Approved Co.'s Transitional Pass-Through Application For TRIESENCE
Express News | Harrow Inc - Triesence Eligible for Separate Reimbursement in Asc and Hopd Settings From April 2025
Express News | Harrow Inc - CMS Approves Transitional Pass-Through Status for Harrow's Triesence 40 Mg/Ml
Major Shareholder Sells Thousands of Harrow Health Shares!
H.C. Wainwright Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $57
Day Lily : WOW!! Truly perfection! Good for you
🩷